A quick note on Valeant Pharmaceutical short sellers from Wall Street analytics firm, S3 Partners – something to give a little context to hedge fund billionaire Bill Ackman's exit from the company.
ADVERTISEMENT
Here's how much Valeant short sellers have been killing it ever since Bill Ackman got in the stock (VRX)
Of course, "average" is $801 million — so we're talking about the big boys here.
Pershing Square CEO Bill Ackman
"
More from S3:
That considered, now might be time to take some off the table.
ADVERTISEMENT
Or you might take into consideration that despite the fact that even though Valeant beat Wall Street's expectations in its most recent earnings announcement, the stock fell 6% because guidance was weak. The company is looking to refinance its $30 billion in debt and needs to sell assets to make payments, and analysts worry that those sales could cut into the company's revenue.
So maybe you leave it on the table.
JOIN OUR PULSE COMMUNITY!
ADVERTISEMENT
Eyewitness? Submit your stories now via social or:
Email: eyewitness@pulse.ng
ADVERTISEMENT